Companies · Biotechnology

Alung Technologies Inc

PITTSBURGH · Biotechnology

Diligence memoA one-page analyst read on Alung Technologies Inc — recommendation, valuation, rhythm, risks.
$130.6M
Total raised · real
14
Rounds
2.5×
Latest step-up
Top 8%
Sector rank · raised
Series B
Latest stage · inferred · Thu May 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Alung Technologies Inc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.21× the median modeled value of Series B Biotechnology companies in 2019–2021 (118 peers) — value vs value, same stage and era.
Dormant
  • Last raise 5.2 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Alung Technologies Inc behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
16.8 yr record
Peak capital year was 2017 with $111.5M across 3 filings.
Market position
ahead of 93% of Biotechnology peers
Capital scale is ahead of 93% of Biotechnology peers; modeled value is above 63% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Needs review
Row-level filing totals differ from canonical totals, so amendment/superseded filtering should be checked.
What triggered this
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2017: $111.5M across 3 filings.
  • Largest single filing was $37.5M on 2017-03-31.
  • Filing rows sum to $319.4M, while canonical raised total is $130.6M; likely amendments/superseded rows are mixed into the detail view.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
  • Canonical filtering should be tightened before using row-level totals for diligence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Alung Technologies Inc is one of 4291 Biotechnology companies tracked from PITTSBURGH. By capital raised it ranks among the largest (ahead of 93% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
55
Investors (latest)
2021-05-06
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeed · 2009-09-25 Raised $2.6M (real) Modeled valuation $115M (est)Seed2009Series A · 2010-02-09 Raised $6.1M (real) Modeled valuation $221M (est)Seed · 2010-02-09 Raised $3.3M (real) Modeled valuation $146M (est)Series A · 2010-02-09 Raised $14M (real) Modeled valuation $488M (est)Series A2010Series A · 2011-11-11 Raised $6.6M (real) Modeled valuation $239M (est)Series A · 2011-11-11 Raised $10M (real) Modeled valuation $362M (est)Series A · 2011-11-11 Raised $8.8M (real) Modeled valuation $319M (est)Series A2011Series A · 2013-03-28 Raised $9.5M (real) Modeled valuation $343M (est)Series A · 2013-03-28 Raised $7.2M (real) Modeled valuation $261M (est)Series A · 2013-03-28 Raised $15M (real) Modeled valuation $533M (est)Series A2013Series B · 2013-03-28 Raised $16M (real) Modeled valuation $627M (est)Series A · 2014-03-31 Raised $10M (real) Modeled valuation $362M (est)Series B · 2014-03-31 Raised $11M (real) Modeled valuation $430M (est)Series B2014Series A · 2014-03-31 Raised $9.5M (real) Modeled valuation $342M (est)Seed · 2015-04-30 Raised $3.8M (real) Modeled valuation $167M (est)Series A · 2015-04-30 Raised $11M (real) Modeled valuation $392M (est)Series A2015Seed · 2015-04-30 Raised $3.8M (real) Modeled valuation $167M (est)Series B · 2015-04-30 Raised $12M (real) Modeled valuation $476M (est)Series A · 2015-04-30 Raised $11M (real) Modeled valuation $381M (est)Series A2015Series B · 2016-12-27 Raised $2.6M (real) Modeled valuation $103M (est)Seed · 2016-12-27 Raised $2.6M (real) Modeled valuation $114M (est)Series B · 2017-03-31 Raised $37M (real) Modeled valuation $1.5B (est)Series B2017Series B · 2017-03-31 Raised $38M (real) Modeled valuation $1.5B (est)Series B · 2017-03-31 Raised $37M (real) Modeled valuation $1.5B (est)Series B · 2018-12-28 Raised $5.0M (real) Modeled valuation $198M (est)Series B2018Series B · 2019-08-02 Raised $5.0M (real) Modeled valuation $198M (est)Seed · 2020-01-15 Raised $3.3M (real) Modeled valuation $145M (est)Series B · 2020-01-15 Raised $3.3M (real) Modeled valuation $130M (est)Series B2020Series B · 2020-02-10 Raised $3.0M (real) Modeled valuation $119M (est)Series B · 2020-05-20 Raised $2.0M (real) Modeled valuation $79M (est)Series B · 2020-10-30 Raised $5.4M (real) Modeled valuation $187M (est)Series B2020Seed · 2021-05-06 Raised $1.8M (real) Modeled valuation $50M (est)Series B · 2021-05-06 Raised $4.6M (real) Modeled valuation $127M (est)Cumulative $319M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.6M · 2009
Series A$6.1M · 2010
Bridge · Series A-stage$3.3M · 2010smaller follow-on
Series A extension$13.5M · 2010
Series A extension$6.6M · 2011
Series A extension$10.0M · 2011
Series A extension$8.8M · 2011
Series A extension$9.5M · 2013
Series A extension$7.2M · 2013
Series A extension$14.7M · 2013
Series B$15.8M · 2013
Bridge · Series B-stage$10.0M · 2014smaller follow-on
Series B extension$10.8M · 2014
Bridge · Series B-stage$9.5M · 2014smaller follow-on
Bridge · Series B-stage$3.8M · 2015smaller follow-on
Bridge · Series B-stage$10.8M · 2015smaller follow-on
Bridge · Series B-stage$3.8M · 2015smaller follow-on
Series B extension$12.0M · 2015
Bridge · Series B-stage$10.5M · 2015smaller follow-on
Series B extension$2.6M · 2016
Bridge · Series B-stage$2.6M · 2016smaller follow-on
Series B extension$37.4M · 2017
Series B extension$37.5M · 2017
Series B extension$36.6M · 2017
Series B extension$5.0M · 2018
Series B extension$5.0M · 2019
Bridge · Series B-stage$3.3M · 2020smaller follow-on
Series B extension$3.3M · 2020
Series B extension$3.0M · 2020
Series B extension$2.0M · 2020
Series B extension$5.4M · 2020
Bridge · Series B-stage$1.8M · 2021smaller follow-on
Series B extension$4.6M · 2021

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 75%.

Modeled valuation trajectory
$126.6M
Base estimate est.
$9.2M
Conservative case
$414.4M
Upside case
$25.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $114.6M · 2009-09-252009Series A · modeled $221.3M · 2010-02-09Seed · modeled $146.1M · 2010-02-09Series A · modeled $488.0M · 2010-02-09Series A · modeled $239.0M · 2011-11-11Series A · modeled $361.5M · 2011-11-11Series A · modeled $318.6M · 2011-11-11Series A · modeled $342.8M · 2013-03-28Series A · modeled $260.6M · 2013-03-28Series A · modeled $532.9M · 2013-03-28Series B · modeled $626.5M · 2013-03-28Series A · modeled $362.0M · 2014-03-31Series B · modeled $430.4M · 2014-03-31Series A · modeled $342.1M · 2014-03-31Seed · modeled $166.5M · 2015-04-30Series A · modeled $391.8M · 2015-04-30Seed · modeled $166.5M · 2015-04-30Series B · modeled $476.3M · 2015-04-30Series A · modeled $380.7M · 2015-04-30Series B · modeled $103.3M · 2016-12-27Seed · modeled $113.6M · 2016-12-27Series B · modeled $1.5B · 2017-03-31Series B · modeled $1.5B · 2017-03-31Series B · modeled $1.5B · 2017-03-31Series B · modeled $198.4M · 2018-12-28Series B · modeled $198.4M · 2019-08-02Seed · modeled $144.5M · 2020-01-15Series B · modeled $129.5M · 2020-01-15Series B · modeled $119.1M · 2020-02-10Series B · modeled $79.4M · 2020-05-20Series B · modeled $187.2M · 2020-10-30Seed · modeled $50.3M · 2021-05-06Series B · modeled $126.6M · 2021-05-062021
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
5.2 yr
Elapsed time used
5.2 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
4 mo
Avg between rounds
$11.2M/yr
Capital velocity
16.8 yr
On record since
2009
First round
33
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 18× above median
This company$130.6M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.3× of median
This company$4.6M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 2.0× above median
This company$126.6M
Sector median$64.2M

Raised more than 93% of sector peers (real $). Modeled value above 63% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #106 of 118.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Pandion Therapeutics Holdco LLC · Series B Raised $40.0M · modeled $1.6B (est)Ocular Therapeutix, Inc · Series B Raised $81.0M · modeled $1.5B (est)Insilico Medicine Cayman TopCo · Series B Raised $36.8M · modeled $1.5B (est)Purigen Biosystems, Inc. · Series B Raised $61.9M · modeled $1.4B (est)Lucira Health, Inc. · Series B Raised $32.5M · modeled $1.3B (est)Peptilogics, Inc. · Series B Raised $40.9M · modeled $1.2B (est)Nanotech Energy, Inc. · Series B Raised $31.6M · modeled $1.1B (est)Windtree Therapeutics Inc /De/ · Series B Raised $104.5M · modeled $1.0B (est)Liminal BioSciences Inc. · Series B Raised $67.1M · modeled $1.0B (est)Palladio Biosciences, Inc. · Series B Raised $28.0M · modeled $1.0B (est)Faze Medicines, Inc. · Series B Raised $30.4M · modeled $998.4M (est)Inivata Ltd · Series B Raised $25.0M · modeled $992.2M (est)Alung Technologies Inc (this company) Raised $130.6M · modeled $126.6M (est)Alung Technologies Inc
CompanyStageRaised · realValue · estvs peer med.
Pandion Therapeutics Holdco LLCSeries B$40.0M$1.6B2.58×
Ocular Therapeutix, IncSeries B$81.0M$1.5B2.42×
Insilico Medicine Cayman TopCoSeries B$36.8M$1.5B2.37×
Purigen Biosystems, Inc.Series B$61.9M$1.4B2.22×
Lucira Health, Inc.Series B$32.5M$1.3B2.10×
Peptilogics, Inc.Series B$40.9M$1.2B1.90×
Nanotech Energy, Inc.Series B$31.6M$1.1B1.82×
Windtree Therapeutics Inc /De/Series B$104.5M$1.0B1.71×
Liminal BioSciences Inc.Series B$67.1M$1.0B1.67×
Palladio Biosciences, Inc.Series B$28.0M$1.0B1.63×
Faze Medicines, Inc.Series B$30.4M$998.4M1.62×
Inivata LtdSeries B$25.0M$992.2M1.61×
Alung Technologies Inc this companySeries B$130.6M$126.6M0.21×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.6M2009-09-25$12.9M$114.6M85%
Series A$6.1M2010-02-09$27.8M$221.3M85%
Seed$3.3M2010-02-09$16.5M$146.1M85%
Series A$13.5M2010-02-09$61.4M$488.0M85%
Series A$6.6M2011-11-11$30.0M$239.0M85%
Series A$10.0M2011-11-11$45.5M$361.5M85%
Series A$8.8M2011-11-11$40.1M$318.6M85%
Series A$9.5M2013-03-28$43.1M$342.8M85%
Series A$7.2M2013-03-28$32.8M$260.6M85%
Series A$14.7M2013-03-28$67.0M$532.9M85%
Series B$15.8M2013-03-28$87.7M$626.5M85%
Series A$10.0M2014-03-31$45.5M$362.0M85%
Series B$10.8M2014-03-31$60.2M$430.4M85%
Series A$9.5M2014-03-31$43.0M$342.1M85%
Seed$3.8M2015-04-30$18.8M$166.5M85%
Series A$10.8M2015-04-30$49.3M$391.8M85%
Seed$3.8M2015-04-30$18.8M$166.5M85%
Series B$12.0M2015-04-30$66.7M$476.3M85%
Series A$10.5M2015-04-30$47.9M$380.7M85%
Series B$2.6M2016-12-27$14.5M$103.3M90%
Seed$2.6M2016-12-27$12.8M$113.6M90%
Series B$37.4M2017-03-31$207.9M$1.5B90%
Series B$37.5M2017-03-31$208.6M$1.5B90%
Series B$36.6M2017-03-31$203.1M$1.5B90%
Series B$5.0M2018-12-28$27.8M$198.4M90%
Series B$5.0M2019-08-02$27.8M$198.4M90%
Seed$3.3M2020-01-15$16.3M$144.5M90%
Series B$3.3M2020-01-15$18.1M$129.5M90%
Series B$3.0M2020-02-10$16.7M$119.1M90%
Series B$2.0M2020-05-20$11.1M$79.4M90%
Series B$5.4M2020-10-30$30.2M$187.2M90%
Seed$1.8M2021-05-06$9.1M$50.3M90%
Series B$4.6M2021-05-06$25.5M$126.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.6M2009-09-25
    • First recorded raise — entered as Seed.
    • 18 investors on this round.
  2. Series A$6.1M2010-02-09
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 2.4× larger than the prior — scaling up.
    • 22 investors on this round.
  3. Seed$3.3M2010-02-09
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.9× smaller than the prior — bridge or down round.
    • 12 investors on this round.
  4. Series A$13.5M2010-02-09
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 4.1× larger than the prior — scaling up.
    • 62 investors on this round.
  5. Series A$6.6M2011-11-11
    • Raised again after 21 mo — slower than the ~14 mo sector norm.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 36 investors on this round.
  6. Series A$10.0M2011-11-11
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.5× larger than the prior — scaling up.
    • 42 investors on this round.
  7. Series A$8.8M2011-11-11
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 40 investors on this round.
  8. Series A$9.5M2013-03-28
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • Revenue band moved No revenue → $0–$1M.
    • 42 investors on this round.
  9. Series A$7.2M2013-03-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.3× smaller than the prior — bridge or down round.
    • 33 investors on this round.
  10. Series A$14.7M2013-03-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× larger than the prior — scaling up.
    • 48 investors on this round.
  11. Series B$15.8M2013-03-28
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 55 investors on this round.
  12. Series A$10.0M2014-03-31
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 1.6× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 69 investors on this round.
  13. Series B$10.8M2014-03-31
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 109 investors on this round.
  14. Series A$9.5M2014-03-31
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 67 investors on this round.
  15. Seed$3.8M2015-04-30
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 2.5× smaller than the prior — bridge or down round.
    • Revenue band moved $0–$1M → $1M–$5M.
    • 31 investors on this round.
  16. Series A$10.8M2015-04-30
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.9× larger than the prior — scaling up.
    • 63 investors on this round.
  17. Seed$3.8M2015-04-30
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.9× smaller than the prior — bridge or down round.
    • 31 investors on this round.
  18. Series B$12.0M2015-04-30
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.2× larger than the prior — scaling up.
    • 79 investors on this round.
  19. Series A$10.5M2015-04-30
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 57 investors on this round.
  20. Series B$2.6M2016-12-27
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 4.0× smaller than the prior — bridge or down round.
    • 37 investors on this round.
  21. Seed$2.6M2016-12-27
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 36 investors on this round.
  22. Series B$37.4M2017-03-31
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 14.6× larger than the prior — scaling up.
    • 95 investors on this round.
  23. Series B$37.5M2017-03-31
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 96 investors on this round.
  24. Series B$36.6M2017-03-31
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 93 investors on this round.
  25. Series B$5.0M2018-12-28
    • Raised again after 21 mo — slower than the ~14 mo sector norm.
    • Round 7.3× smaller than the prior — bridge or down round.
    • 61 investors on this round.
  26. Series B$5.0M2019-08-02
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 48 investors on this round.
  27. Seed$3.3M2020-01-15
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 1.5× smaller than the prior — bridge or down round.
    • 51 investors on this round.
  28. Series B$3.3M2020-01-15
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 52 investors on this round.
  29. Series B$3.0M2020-02-10
    • Came back fast: 1 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  30. Series B$2.0M2020-05-20
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 1.5× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  31. Series B$5.4M2020-10-30
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 2.7× larger than the prior — scaling up.
    • 47 investors on this round.
  32. Seed$1.8M2021-05-06
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 3.0× smaller than the prior — bridge or down round.
    • 7 investors on this round.
  33. Series B$4.6M2021-05-06
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.5× larger than the prior — scaling up.
    • 55 investors on this round.
Intelligence
2021 ~Q3
Modeled next raise · ~4mo cadence
$11.6M
Modeled next size est.range $7.6M$18.6M
2.5×
Last step-up
$11.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
John J. McIlwraith2 other2013-03
Peter M. DeComo1 other2009-09
Adam G. Seiver2020-01
Adam J Seiver2017-03
David J. Haffner2015-04
David L. Motley2015-04
David M. Motley2019-08
Gary G. Glausser2015-04
Gary J Glausser2011-11
Gerald E. McGinnis2009-09
Jeanne J. Cunicelli2017-03
Jeanne J. Cunnicelli2017-03
John E. McIlwraith2015-04
John G. Kuzmishin2020-05
John J. McIllwraith2014-03
Joseph J Stevens2010-02
Joseph J Stevens III2011-11
Kraig J. McEwen2014-03
Louis E. Choy2009-09
Nicholas E. Cullen2015-04
Nicholas J Cullen2011-11
Nicholas J. Kuhn2009-09
William B Ross2011-11
William E. Ross2009-09
Registry & provenance

Alung Technologies Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1179295
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Tarveda Therapeutics, Inc.BiotechnologySeries B$127.4M$141.7Msame sector · same stage
PolyPid Ltd.BiotechnologySeries B$125.4M$126.1Msame sector · same stage
DiaMedica Therapeutics Inc.BiotechnologySeries B$110.4M$136.1Msame sector · same stage
ReAlta Life Sciences, Inc.BiotechnologySeries B$108.3M$145.9Msame sector · same stage
Vaxinnate CorpBiotechnologySeries B$92.6M$128.9Msame sector · same stage
EvolveImmune Therapeutics Holding Company, LLCBiotechnologySeries B$85.8M$124.8Msame sector · same stage
Instylla, Inc.BiotechnologySeries B$85.5M$100.2Msame sector · same stage
Oncocyte CorpBiotechnologySeries B$83.0M$119.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Aloft Biotechnologies, Inc.BiotechnologyPre-Seed$398K89%
Alume Biosciences IncBiotechnologySeries A$18.9M89%
Alveo Technologies Inc.BiotechnologySeries C$503.0M88%
Alzheon, Inc.BiotechnologySeries D+$1.6B88%
Alumis Inc.BiotechnologySeries D+$432.7M88%
Aluvis International, Inc.BiotechnologyPre-Seed$35.9M87%
ALRGN Bio, Inc.BiotechnologyPre-Seed$52.2M87%
Alder Biopharmaceuticals IncBiotechnologySeries C$4.1B86%
Frequently asked
How much funding has Alung Technologies Inc raised?
Alung Technologies Inc has raised approximately $130.6M in disclosed capital across 14 recorded financing rounds, aggregated from public filings.
What is Alung Technologies Inc's estimated valuation?
Provath's modeled valuation for Alung Technologies Inc is approximately $126.6M (modeled range $9.2M–$414.4M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Alung Technologies Inc at?
Alung Technologies Inc's latest modeled financing stage is Series B. Its most recent recorded round closed around Thu May 06.
What does Alung Technologies Inc do and where is it based?
Alung Technologies Inc operates in the Biotechnology sector, based in PITTSBURGH.
Explore related

See where Alung Technologies Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Alung Technologies Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.